LXN and prostate carcinoma: The datasets revealed the intrinsic differences in the proteomes of cancer cells (MCF-7 and PC3) and their normal counterparts without zinc treatment, such as the downregulation of antitumour proteins (14-3-3 protein σ, protein S100A2, latexin, and annexin A1) and the upregulation of tumour protein (hD53), antioxidants (peroxiredoxin 6 and superoxide dismutase), and metabolic enzymes (dihydrolipoamide S-succinyltransferase and aldehyde dehydrogenase 1) in both breast and prostate cancer cells.